{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-000383","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2024-01-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.907979+00:00","generated_at":"2026-06-06T21:26:35.795153+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xilio receives Nasdaq deficiency notice for bid price below $1.00/share","bullets":["Bid price closed below $1.00 for 30 consecutive business days; violates Minimum Bid Requirement.","180-day cure period expires July 17, 2024; must trade at $1.00+ for 10 consecutive days to regain compliance.","May be eligible for extra 180-day period if transfer to Nasdaq Capital Market; no guarantee of success.","Company will monitor bid price and evaluate options; potential delisting risk remains."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-000383","json":"https://secwatch.observer/filing/0001558370-24-000383.json","markdown":"https://secwatch.observer/filing/0001558370-24-000383.md","text":"https://secwatch.observer/filing/0001558370-24-000383.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024000383/0001558370-24-000383-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024000383/xlo-20240119x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T21:26:35.795153+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dfb0a6f1b9d90f54c090ae6c91685fb66a5dabfa","claim":"Xilio Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).","evidence_excerpt":"January 19, 2024, Xilio Therapeutics, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, which is the minimum bid price required to maintain continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). ​ The Notice has no immediate effect on the listing of the Company’s com","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024000383/0001558370-24-000383-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}